Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385297532> ?p ?o ?g. }
- W4385297532 abstract "Chronic liver disease is a major cause of premature death in sub-Saharan Africa. Efficacy of antiviral therapy among patients with hepatitis B virus (HBV)-related cirrhosis is not well established in Africa. We described the clinical characteristics and outcomes of patients with cirrhosis and hepatocellular carcinoma in The Gambia and assessed the impact of tenofovir disoproxil fumarate (TDF) on survival of HBV-infected patients with cirrhosis.In this prospective cohort study, we followed up adults who were consecutively diagnosed with cirrhosis or hepatocellular carcinoma between 2012 and 2015 in The Gambia, west Africa. Patients with chronic HBV infection and cirrhosis, without hepatocellular carcinoma, were offered TDF. Primary outcome was overall survival. To determine the effect of TDF on survival, we performed a Cox proportional hazard regression model with inverse probability of treatment weighting (IPTW) based on propensity score.Of 529 patients enrolled in this study, 336 patients (252 with hepatocellular carcinoma and 84 with cirrhosis) were analysed. Patients were predominantly male (253 [75%] men and 83 [25%] women), with a median age of 42 years (IQR 33-55). 276 (84%) of 327 of patients with data were positive for HBV biomarkers, 31 (10%) of 311 were positive for hepatitis C virus antibodies, and 22 (10%) of 223 were positive for hepatitis D virus antibodies. 64% of patients with hepatocellular carcinoma had multifocal tumour, with a median size of 7·5 cm (IQR 5·4-10·8). 173 patients with hepatocellular carcinoma and 70 patients with cirrhosis were included in the survival analysis. Median survival was 1·5 months (95% CI 1·1-2·0) in patients with hepatocellular carcinoma and 17·1 months (11·2-24·0) in patients with cirrhosis (log-rank p<0·0001). In patients with hepatocellular carcinoma, ascites (hazard ratio [HR] 1·78, 95% CI 1·21-2·60), partial or complete portal thrombosis (HR 2·61, 1·58-4·30), and platelet count (HR 1·80, 1·19-2·70) were independent predictive factors of mortality at baseline. In HBV-infected patients with cirrhosis, median turnaround time between cirrhosis diagnosis and TDF initiation was 4·9 months (IQR 3·2-7·3). In IPTW analysis, TDF treatment was associated with improved survival in patients with HBV-related cirrhosis (adjusted HR 0·14, 0·06-0·34; p<0·0001).These results highlight poor survival of patients with cirrhosis or hepatocellular carcinoma as well as the effectiveness of TDF in reducing the premature mortality of patients with cirrhosis and HBV infection. Interventions for early diagnosis and treatment of cirrhosis as well as screening programmes for hepatocellular carcinoma are urgently required in Africa.European Commission and Medical Research Council UK.For the French translation of the abstract see Supplementary Materials section." @default.
- W4385297532 created "2023-07-28" @default.
- W4385297532 creator A5009137335 @default.
- W4385297532 creator A5017208288 @default.
- W4385297532 creator A5019539147 @default.
- W4385297532 creator A5022575375 @default.
- W4385297532 creator A5023606749 @default.
- W4385297532 creator A5031576158 @default.
- W4385297532 creator A5032796349 @default.
- W4385297532 creator A5033754121 @default.
- W4385297532 creator A5033814981 @default.
- W4385297532 creator A5041240350 @default.
- W4385297532 creator A5046327966 @default.
- W4385297532 creator A5052134574 @default.
- W4385297532 creator A5055089333 @default.
- W4385297532 creator A5065171938 @default.
- W4385297532 creator A5078690060 @default.
- W4385297532 creator A5081996617 @default.
- W4385297532 creator A5085273356 @default.
- W4385297532 creator A5089789885 @default.
- W4385297532 date "2023-07-01" @default.
- W4385297532 modified "2023-10-05" @default.
- W4385297532 title "Clinical characteristics and outcomes of patients with cirrhosis and hepatocellular carcinoma in The Gambia, west Africa: a prospective cohort study" @default.
- W4385297532 cites W1584326990 @default.
- W4385297532 cites W1850144958 @default.
- W4385297532 cites W1945511967 @default.
- W4385297532 cites W1964051982 @default.
- W4385297532 cites W1978121984 @default.
- W4385297532 cites W1994773465 @default.
- W4385297532 cites W2030402743 @default.
- W4385297532 cites W2031756259 @default.
- W4385297532 cites W2042112823 @default.
- W4385297532 cites W2119190881 @default.
- W4385297532 cites W2124273275 @default.
- W4385297532 cites W2163403599 @default.
- W4385297532 cites W2471570375 @default.
- W4385297532 cites W2475385134 @default.
- W4385297532 cites W2519375936 @default.
- W4385297532 cites W2558644206 @default.
- W4385297532 cites W2605785536 @default.
- W4385297532 cites W2761031851 @default.
- W4385297532 cites W2788473137 @default.
- W4385297532 cites W2792615707 @default.
- W4385297532 cites W2802906787 @default.
- W4385297532 cites W2910488439 @default.
- W4385297532 cites W3001593440 @default.
- W4385297532 cites W3002179283 @default.
- W4385297532 cites W3019175774 @default.
- W4385297532 cites W4280569105 @default.
- W4385297532 cites W4284892362 @default.
- W4385297532 cites W4302022990 @default.
- W4385297532 doi "https://doi.org/10.1016/s2214-109x(23)00263-2" @default.
- W4385297532 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37517420" @default.
- W4385297532 hasPublicationYear "2023" @default.
- W4385297532 type Work @default.
- W4385297532 citedByCount "1" @default.
- W4385297532 countsByYear W43852975322023 @default.
- W4385297532 crossrefType "journal-article" @default.
- W4385297532 hasAuthorship W4385297532A5009137335 @default.
- W4385297532 hasAuthorship W4385297532A5017208288 @default.
- W4385297532 hasAuthorship W4385297532A5019539147 @default.
- W4385297532 hasAuthorship W4385297532A5022575375 @default.
- W4385297532 hasAuthorship W4385297532A5023606749 @default.
- W4385297532 hasAuthorship W4385297532A5031576158 @default.
- W4385297532 hasAuthorship W4385297532A5032796349 @default.
- W4385297532 hasAuthorship W4385297532A5033754121 @default.
- W4385297532 hasAuthorship W4385297532A5033814981 @default.
- W4385297532 hasAuthorship W4385297532A5041240350 @default.
- W4385297532 hasAuthorship W4385297532A5046327966 @default.
- W4385297532 hasAuthorship W4385297532A5052134574 @default.
- W4385297532 hasAuthorship W4385297532A5055089333 @default.
- W4385297532 hasAuthorship W4385297532A5065171938 @default.
- W4385297532 hasAuthorship W4385297532A5078690060 @default.
- W4385297532 hasAuthorship W4385297532A5081996617 @default.
- W4385297532 hasAuthorship W4385297532A5085273356 @default.
- W4385297532 hasAuthorship W4385297532A5089789885 @default.
- W4385297532 hasConcept C126322002 @default.
- W4385297532 hasConcept C188816634 @default.
- W4385297532 hasConcept C203014093 @default.
- W4385297532 hasConcept C207103383 @default.
- W4385297532 hasConcept C2522874641 @default.
- W4385297532 hasConcept C2777214474 @default.
- W4385297532 hasConcept C2777382497 @default.
- W4385297532 hasConcept C2778019345 @default.
- W4385297532 hasConcept C2780593183 @default.
- W4385297532 hasConcept C44249647 @default.
- W4385297532 hasConcept C50382708 @default.
- W4385297532 hasConcept C71924100 @default.
- W4385297532 hasConcept C72563966 @default.
- W4385297532 hasConcept C90924648 @default.
- W4385297532 hasConceptScore W4385297532C126322002 @default.
- W4385297532 hasConceptScore W4385297532C188816634 @default.
- W4385297532 hasConceptScore W4385297532C203014093 @default.
- W4385297532 hasConceptScore W4385297532C207103383 @default.
- W4385297532 hasConceptScore W4385297532C2522874641 @default.
- W4385297532 hasConceptScore W4385297532C2777214474 @default.
- W4385297532 hasConceptScore W4385297532C2777382497 @default.
- W4385297532 hasConceptScore W4385297532C2778019345 @default.
- W4385297532 hasConceptScore W4385297532C2780593183 @default.
- W4385297532 hasConceptScore W4385297532C44249647 @default.